| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Research and development | NaN | 1,632,581 | NaN | NaN |
| General and administrative | NaN | 10,279,981 | NaN | NaN |
| Total operating expenses | NaN | 11,912,562 | NaN | NaN |
| Loss from operations | NaN | -11,912,562 | NaN | NaN |
| Unrealized gain on digital assets | NaN | 1,812,348 | NaN | NaN |
| Realized gain on sale of digital assets | NaN | 4,197,394 | NaN | NaN |
| Trading gains, net | NaN | 97 | NaN | NaN |
| Foreign currency transaction loss | NaN | -521 | NaN | NaN |
| Change in fv of warrant liability | NaN | 0 | NaN | NaN |
| Change in fv of derivative | NaN | -55,146 | NaN | NaN |
| Interest income | NaN | 107,595 | NaN | NaN |
| Interest expense | NaN | 283,011 | NaN | NaN |
| Stock based compensation - stock options and warrants | NaN | 1,331,079 | 42,674 | 192,053 |
| Total other income (expense), net | NaN | 5,911,425 | NaN | NaN |
| Net loss | -35,059,852 | -1,155,292 | -1,781,255 | -3,064,590 |
| Accounts payable and accrued expenses | NaN | NaN | 448,494 | -472,052 |
| Stock based compensation - option grants | 114,166 | 0 | 0 | 1,700,000 |
| Change in fair value of warrant liability | NaN | 0 | -12,859 | -9,518 |
| Advisory shares committed for issuance | 8,113,318 | NaN | NaN | NaN |
| Depreciation & amortization expense | 20,044 | 3,985 | 1,489 | 232 |
| Accrued interest expense - related parties | NaN | NaN | 6,301 | 21,253 |
| Change in fair value of derivative liability | 48,279 | 55,146 | NaN | NaN |
| Interest expense | 8,387 | 243,177 | 1 | 39,832 |
| Accretion on convertible notes | 851,018 | NaN | NaN | NaN |
| Unrealized gain from changes in fair value of digital assets | -22,061,472 | 6,009,838 | NaN | NaN |
| Non-cash digital asset operating expenses | 8,726 | 2,429,487 | NaN | NaN |
| Prepaid expenses and other current assets | 273,390 | 193,457 | 431,011 | 1,788,619 |
| Accounts payable and accrued expenses | 2,134,541 | -408,201 | NaN | NaN |
| Operating lease liability | 2,122 | NaN | NaN | NaN |
| Net cash used in operating activities | -2,067,727 | -3,818,202 | -1,726,166 | -3,381,409 |
| Cash from short term investments | NaN | 2,000,000 | NaN | NaN |
| Restricted cash | NaN | 8,000,000 | NaN | NaN |
| Redemption of short term investments | -500,000 | NaN | NaN | NaN |
| Purchases of pp&e | 9,394 | 21,424 | 22,540 | 13,369 |
| Cash paid to acquire operating lease | NaN | 18,363 | NaN | NaN |
| Cash acquired in accordance with merger | NaN | -15,345 | NaN | NaN |
| Net cash provided by investing activities | 490,606 | -10,024,442 | -22,540 | -13,369 |
| Cash advances paid to related parties | NaN | 250,000 | 0 | 93,800 |
| Cash advances from related parties | NaN | 11,900 | 0 | 17,400 |
| Cash proceeds from issuance of common stock in ipo | NaN | -323,319 | 0 | 11,953,046 |
| Proceeds from notes payable - related parties | NaN | 100 | 0 | 250,000 |
| Proceeds from notes payable | 995,000 | 10,000,000 | NaN | NaN |
| Payment of issuance costs | 75,000 | 946,000 | NaN | NaN |
| Net cash provided by financing activities | 920,000 | 8,492,681 | 0 | 12,126,646 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | -657,121 | -5,349,962 | -1,748,706 | 8,731,868 |
| Cash and cash equivalents, beginning of period | 1,636,655 | NaN | 3,455 | NaN |
| Restricted cash | 8,000,000 | 8,000,000 | NaN | NaN |
| Cash, cash equivalents, and restricted cash, end of period | 8,979,534 | 3,455 | 6,986,617 | NaN |
| Total cash, cash equivalents, and restricted cash | 8,979,534 | NaN | NaN | NaN |
Apimeds Pharmaceuticals US, Inc. (APUS)
Apimeds Pharmaceuticals US, Inc. (APUS)